Researchers at the Duke University Medical Center have discovered a biomarker which has been compared to finding a “Holy Grail” (by David Goldstein of Duke’s Institute for Genome Sciences & Policy).
The biomarker is an innovation in Hepatitis C treatment which can be used to presage how different patients will react to treatment and also can be used to explain why different racial and ethnic groups fluctuate so much in their response to treatment.
The discovery of the marker, the result of a single letter change (C to T), has given patients and doctors valuable information in terms of deciding the best treatment for each individual. This information is so important as "The side effects of hepatitis treatment can be brutal, and about half the time, the treatment fails to eradicate the virus.” said Goldstein.
Review by Rachael Lee, 18.08.2009
from:
and:
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment